Inhibition of Drp1-mediated mitochondrial fission improves mitochondrial dynamics and bioenergetics stimulating neurogenesis in hippocampal progenitor cells from a Down syndrome mouse model

Biochim Biophys Acta Mol Basis Dis. 2017 Dec;1863(12):3117-3127. doi: 10.1016/j.bbadis.2017.09.014. Epub 2017 Sep 20.

Abstract

Functional and structural damages to mitochondria have been critically associated with the pathogenesis of Down syndrome (DS), a human multifactorial disease caused by trisomy of chromosome 21 and associated with neurodevelopmental delay, intellectual disability and early neurodegeneration. Recently, we demonstrated in neural progenitor cells (NPCs) isolated from the hippocampus of Ts65Dn mice -a widely used model of DS - a severe impairment of mitochondrial bioenergetics and biogenesis and reduced NPC proliferation. Here we further investigated the origin of mitochondrial dysfunction in DS and explored a possible mechanistic link among alteration of mitochondrial dynamics, mitochondrial dysfunctions and defective neurogenesis in DS. We first analyzed mitochondrial network and structure by both confocal and transmission electron microscopy as well as by evaluating the levels of key proteins involved in the fission and fusion machinery. We found a fragmentation of mitochondria due to an increase in mitochondrial fission associated with an up-regulation of dynamin-related protein 1 (Drp1), and a decrease in mitochondrial fusion associated with a down-regulation of mitofusin 2 (Mnf2) and increased proteolysis of optic atrophy 1 (Opa1). Next, using the well-known neuroprotective agent mitochondrial division inhibitor 1 (Mdivi-1), we assessed whether the inhibition of mitochondrial fission might reverse alteration of mitochondrial dynamics and mitochondrial dysfunctions in DS neural progenitors cells. We demonstrate here for the first time, that Mdivi-1 restores mitochondrial network organization, mitochondrial energy production and ultimately improves proliferation and neuronal differentiation of NPCs. This research paves the way for the discovery of new therapeutic tools in managing some DS-associated clinical manifestations.

Keywords: Down syndrome; Drp1; Hippocampal neurogenesis; Mdivi-1; Mitochondrial dysfunction; Mitochondrial network.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Proliferation
  • Disease Models, Animal
  • Down Syndrome / metabolism*
  • Down Syndrome / pathology*
  • Dynamins / antagonists & inhibitors
  • Dynamins / metabolism*
  • Energy Metabolism
  • GTP Phosphohydrolases / metabolism
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Mice
  • Mitochondria / metabolism*
  • Mitochondrial Dynamics / physiology*
  • Neurogenesis / physiology*
  • Optic Atrophy, Autosomal Dominant / metabolism
  • Quinazolinones / antagonists & inhibitors
  • Quinazolinones / metabolism

Substances

  • 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone
  • Quinazolinones
  • GTP Phosphohydrolases
  • Mfn2 protein, mouse
  • Dnm1l protein, mouse
  • Dynamins